20:40 , Jan 18, 2019 |  BC Week In Review  |  Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
01:07 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Anxiety Mouse studies suggest depleting senescent cells could help treat obesity-induced anxiety. In a transgenic mouse model of obesity expressing the senescence marker human CDKN2A, a tool compound that depletes CDKN2A-positive cells decreased anxiety-like...
01:46 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

FDA approves BMS's Sprycel for pediatric ALL

FDA approved an sNDA from Bristol-Myers Squibb Co. (NYSE:BMY) to expand the label of Sprycel dasatinib to include treatment of pediatric patients ages one and older with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
20:10 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Mouse studies suggest the pan-BCR-ABL tyrosine kinase inhibitor (TKI) Iclusig ponatinib could help treat cerebral cavernous malformation (CCM). In three mouse models of CCM, Iclusig decreased hindbrain lesion volume and counts compared with...
15:19 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Gastrointestinal cancer Cell culture and mouse studies identified a quinazoline-based compound that could help treat c-Kit- and PDGFR-mutant gastrointestinal stromal tumors (GISTs). Chemical synthesis of phenoxyquinazoline- and quinolone-based PDGFRA inhibitors followed by testing in...
18:20 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Aug. 20 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical...
19:48 , Aug 23, 2018 |  BC Extra  |  Tools & Techniques

Computational tool prospectively predicts resistance to cancer drugs

An Institute of Cancer Research team has developed a computational prediction tool that can predict which resistant mutations will develop in response to cancer drugs before a patient takes the drug. The results suggest the...
19:47 , Aug 20, 2018 |  BC Extra  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Monday to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical candidates...
16:42 , Jul 20, 2018 |  BC Week In Review  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced on July 18 that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its...